Biktarvy should be adjusted according to physiological conditions when used in special populations. Maternal and infant risks should be evaluated during pregnancy, and dosage adjustments should be made for patients with liver and kidney dysfunction. Individualized administration is recommended for elderly and pediatric patients, and strict monitoring can ensure treatment safety.

1. Medication for Pregnant Women

(1) The existing data does not show any teratogenic effects of Betuximab on fetuses, but the use during pregnancy still needs to be balanced between HIV control and potential risks.

(2) It is recommended that newborns receive 6-week zidovudine prophylaxis after delivery to reduce the risk of vertical transmission.

2. Medication for lactating women

(1) HIV infected mothers should avoid breastfeeding to prevent the virus from spreading through breast milk.

(2) It is not yet clear whether the drug ingredients are secreted into breast milk, and it is recommended to switch to formula milk powder feeding.

3. Pediatric patient medication

(1) Teenagers weighing ≥ 25kg can use adult doses, while children with smaller weights need to adjust their doses.

(2) The safety data for children under 3 years old is insufficient, and the use of this compound preparation is not recommended.

4. Medication for elderly patients

(1) Patients over 65 years old do not need routine dose adjustments, but need to strengthen renal function monitoring.

(2) When combining multiple chronic diseases, it is necessary to evaluate the risk of drug interactions.

5. Patients with liver dysfunction

(1) Mild to moderate damage does not require dose adjustment, but ALT/AST monitoring is required every 2 weeks.

(2) Severe liver dysfunction (Child Pugh C grade) is contraindicated, which may increase the toxicity of tenofovir.

6. Patients with renal insufficiency

(1) When the creatinine clearance rate is 30-50ml/min, it needs to be adjusted to be administered once every 48 hours.

(2) Creatinine clearance rate<30ml/min or dialysis patients should not use it, as emtricitabine may accumulate.